Document is current
Any future updates will be listed below
-
Authors
Arya, Shahrzad
Ventin, Marco
Cattaneo, Giulia
Nebbia, Martina
Sanatkar, Seyed Amir
Martin, Cristina
Jia, Jingyu
Kim, Bangjin
Bailey, Cedric A.
Bardeesy, Nabeel M.
Ting, David T.
Deshpande, Vikram
Wang, Xinhui
Ryeom, Sandra
Ferrone, Soldano
Ferrone, Cristina R.
-
Funding
Funding for this research was provided by:
Cholangiocarcinoma Foundation Award AstraZeneca/CCF Research Fellowship (AWD00001136)
The Dana-Faber/Harvard Cancer Center (DF/HCC) SPORE grant in Gastrointestinal Cancer (P50CA127003)
Department of Defense Award (HT9425-23-1-0886)
- License Information
-
More Information
Article History
Received: 27 June 2025
Accepted: 27 April 2026
First Online: 4 June 2026
Declarations
:
: All animal studies were approved by the Institutional Animal Care and Use Committees (IACUC) at Massachusetts General Hospital and Cedars-Sinai Medical Center and conducted in accordance with their institutional guidelines. The maximal tumor burden permitted by the IACUC was not exceeded in any experiment. No human subjects were involved in this study.
: Not applicable.
: The authors declare no competing interests.
